RespireRx Pharmaceuticals Inc (fka RSPI)

[davidal66]

Let's agree for the sake of discussion Varney made the right move to hold off on unblinding the sleep apnea study as not to disrupt RD negotiations and to scare off a RD(or other)partner.

On the verge of a major shareholder meeting and new financing, running out of money, with some obvious games, issues being played, by the RD partner with the last signature delayed and delayed once more, it would seem like a grand time to roll the dice and unblind the sleep apnea data set. I doubt it would have much of a negative effect on the share price, or valuaiton if negative... it could only help if there is biological activity.